Bioheart, Inc.

Trial data on stem cell treatment of heart failure presented

Published in Aging and Elder Health Week, January 23rd, 2005

At the recent American Heart Association Meeting in New Orleans, Bioheart, Inc., released 1-year follow-up data from phase I/II studies conducted in Europe utilizing MyoCell (adult muscle stem cells - myoblasts), delivered percutaneously via the MyoCath needle catheter to repair damaged heart muscle.

This low dose study was primarily designed to evaluate safety and provide preliminary efficacy information for the use of the MyoCell and MyoCath technologies in patients with Congestive Heart Failure (CHF). Patients selected to participate in the clinical trials exhibited symptoms on average that were consistent with NYHA Class III heart failure patients. The first patient...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Aging and Elder Health Week

Source: Aging and Elder Health Week (2005-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry